Published :
Tables : 43
Figures : 41
Category : Healthcare
No. of Pages : 210
Report Code : HC-1062
Resistant Depression Treatment Market is foreseen to value over CAGR of 3% during the forecast period of 2022-2028. According to the World Health Organization around 300 million people around the world have depression. At present switching antidepressants, increasing dosages, allowing more time for medications to work, augmented medication for other conditions, neuro-stimulation and psychotherapy are some of the ways for resistant depression treatment. However, burgeoning demand to counter the therapeutic challenge resulted in the emergence of innovative resistant depression treatment. Recently ketamine-based depression treatments are gaining preference as major biopharmaceutical companies receive a green signal from the Food and Drug Administration (FDA). Some of the factors that are driving the global resistant depression treatment market include: • Rise in demand for antidepressant treatment due to increasing mental health issues • Burden on the healthcare system due to nonresponding patients to a combination of antidepressants • Ageing population as well as increased anxiety and depression syndrome in the millennials • Ineffectiveness of antidepressants due to an individual’s genetic composition • Exposure to addictive substances that prevent antidepressant medications to positively treat patients Stigma related to depressive disorder treatments, patent expiration, fear of drug withdrawals, high cost, lack of substantial clinical trials to gauge the efficacy of resistant depression medicines contribute as the major restraints to the global resistant depression treatment market. High prevalence of depression and mental disorders with substantial treatment resistance in Europe and North America are indicative of progressive growth of the market. Increasing awareness about mental health and related treatments are anticipated to create greater opportunities in the near future amongst the emerging nations in the Asia-Pacific and rest of the world. Resistant Depression Treatment Key Market Players: Roche Holding, Johnson & Johnson, Merck & CO., Novartis AG, Pfizer Inc., Janssen Pharmaceuticals, Seelos Therapeutics, Bristol-Myers Squibb, GlaxoSmithKline plc and others Resistant Depression Treatment Market Segmentation : By Drug Type • Selective serotonin reuptake inhibitors • Serotonin-norepinephrine reuptake inhibitors • Tricyclic antidepressants • Monoamine oxidase inhibitors • Atypical agents By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Mail Order Pharmacies By Region • North America • Latin America • Europe • Asia Pacific • Middle East and Africa Competitive Landscape: • Tier 1 players - established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global resistant depression treatment market on the basis of drug type, distribution channel, and region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Resistant Depression Treatment Market is foreseen to value over CAGR of 3% during the forecast period of 2022-2028.
According to the World Health Organization around 300 million people around the world have depression. At present switching antidepressants, increasing dosages, allowing more time for medications to work, augmented medication for other conditions, neuro-stimulation and psychotherapy are some of the ways for resistant depression treatment. However, burgeoning demand to counter the therapeutic challenge resulted in the emergence of innovative resistant depression treatment. Recently ketamine-based depression treatments are gaining preference as major biopharmaceutical companies receive a green signal from the Food and Drug Administration (FDA).
Some of the factors that are driving the global resistant depression treatment market include: • Rise in demand for antidepressant treatment due to increasing mental health issues • Burden on the healthcare system due to nonresponding patients to a combination of antidepressants • Ageing population as well as increased anxiety and depression syndrome in the millennials • Ineffectiveness of antidepressants due to an individual’s genetic composition • Exposure to addictive substances that prevent antidepressant medications to positively treat patients
Stigma related to depressive disorder treatments, patent expiration, fear of drug withdrawals, high cost, lack of substantial clinical trials to gauge the efficacy of resistant depression medicines contribute as the major restraints to the global resistant depression treatment market. High prevalence of depression and mental disorders with substantial treatment resistance in Europe and North America are indicative of progressive growth of the market. Increasing awareness about mental health and related treatments are anticipated to create greater opportunities in the near future amongst the emerging nations in the Asia-Pacific and rest of the world.
Resistant Depression Treatment Key Market Players: Roche Holding, Johnson & Johnson, Merck & CO., Novartis AG, Pfizer Inc., Janssen Pharmaceuticals, Seelos Therapeutics, Bristol-Myers Squibb, GlaxoSmithKline plc and others
Resistant Depression Treatment Market Segmentation : By Drug Type • Selective serotonin reuptake inhibitors • Serotonin-norepinephrine reuptake inhibitors • Tricyclic antidepressants • Monoamine oxidase inhibitors • Atypical agents By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Mail Order Pharmacies By Region • North America • Latin America • Europe • Asia Pacific • Middle East and Africa
Competitive Landscape: • Tier 1 players - established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the global resistant depression treatment market on the basis of drug type, distribution channel, and region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Resistant Depression Treatment Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Resistant Depression Treatment Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Resistant Depression Treatment Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Resistant Depression Treatment Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Resistant Depression Treatment Market, By Drug Type Historical Analysis and Forecast 2022-2027 (USD Million) 7.1. Selective serotonin reuptake inhibitors 7.2. Serotonin-norepinephrine reuptake inhibitors 7.3. Tricyclic antidepressants 7.4 Monoamine oxidase inhibitors 7.5. Atypical agents 8. Global Resistant Depression Treatment Market, By Distribution Channel Historical Analysis and Forecast 2022-2027 (USD Million) 8.1. Hospital Pharmacies 8.2. Retail Pharmacies 8.3. Mail Order Pharmacies 9. North America Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2022-2027 10. Latin America Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2022-2027 11. Europe Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2022-2027 12. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2027 13. Middle East and Africa Market Analysis 2015–2020 and Forecast 2022–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2020 13.2.1. Saudi Arabia 13.2.2. UAE 13.2.3. South Africa 13.2.4. Egypt 13.3. Market Size (USD Million) Forecast for MEA 2022-2027 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 14.1. Roche Holding 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. Johnson & Johnson 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. Merck & CO. 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. Novartis AG 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5 Pfizer Inc. 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6 Janssen Pharmaceuticals 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. Seelos Therapeutics 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Bristol-Myers Squibb 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. GlaxoSmithKline plc 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 15. Pre and Post COVID-19 Impact 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations 16. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Resistant Depression Treatment Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Resistant Depression Treatment Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Resistant Depression Treatment Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Resistant Depression Treatment Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Resistant Depression Treatment Market, By Drug Type Historical Analysis and Forecast 2022-2027 (USD Million) 7.1. Selective serotonin reuptake inhibitors 7.2. Serotonin-norepinephrine reuptake inhibitors 7.3. Tricyclic antidepressants 7.4 Monoamine oxidase inhibitors 7.5. Atypical agents 8. Global Resistant Depression Treatment Market, By Distribution Channel Historical Analysis and Forecast 2022-2027 (USD Million) 8.1. Hospital Pharmacies 8.2. Retail Pharmacies 8.3. Mail Order Pharmacies 9. North America Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2022-2027 10. Latin America Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. Brazil 10.2.2. Venezuela 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (USD Million) Forecast for Latin America 2022-2027 11. Europe Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Rest of Europe 11.3. Market Size (USD Million) Forecast for Europe 2022-2027 12. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Japan 12.2.2. China 12.2.3. India 12.2.4. Australia and New Zealand 12.2.5. ASEAN 12.2.6. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2027 13. Middle East and Africa Market Analysis 2015–2020 and Forecast 2022–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2020 13.2.1. Saudi Arabia 13.2.2. UAE 13.2.3. South Africa 13.2.4. Egypt 13.3. Market Size (USD Million) Forecast for MEA 2022-2027 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 14.1. Roche Holding 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. Johnson & Johnson 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. Merck & CO. 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. Novartis AG 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5 Pfizer Inc. 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6 Janssen Pharmaceuticals 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. Seelos Therapeutics 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Bristol-Myers Squibb 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. GlaxoSmithKline plc 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 15. Pre and Post COVID-19 Impact 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations
16. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics